Amylyx Pharmaceuticals Stock News

Certain stocks are such poor bets that they are likely to lose ground even in bull markets.

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public offering price of $35.50 per share. In addition, Amylyx has granted the underwriters a 30-day option to purchase up to an additional 2,113,500 shares of its...

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of $350.0 million of shares of its common stock. In addition, Amylyx intends to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of its common stock at the public o...

Amylyx Pharmaceuticals (AMLX) shares exploded to the upside on August 18th after the company reported blockbuster topline results from its pivotal Phase 3 LUCIDITY trial. The late-stage study evaluated avexitide – the pharmaceutical firm's first-in-class GLP-1 receptor antagonist – in patients suffering from post-bariatric hypoglycemia (PBH).

Amylyx stock skyrocketed Tuesday after its GLP-1 drug reduced hypoglycemia in patients who've undergone bariatric surgery.

Amylyx Pharmaceuticals says its GLP-1 receptor antagonist, avexitide, met both the primary and secondary endpoints in a late-stage clinical trial.

Amylyx Pharmaceuticals said on Tuesday its experimental drug met its main goal in a late-stage trial for post-bariatric ​hypoglycemia, a condition marked by dangerously low blood sugar ‌levels following weight-loss surgery.

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced positive topline results from LUCIDITY, a 78-participant, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor ...